Skip to main content
Marinomed Biotech AG logo

Marinomed Biotech AG — Investor Relations & Filings

Ticker · MARI ISIN · ATMARINOMED6 LEI · 529900GN3B1EN80XF405 VI Manufacturing
Filings indexed 427 across all filing types
Latest filing 2026-04-30 Declaration of Voting R…
Country AT Austria
Listing VI MARI

About Marinomed Biotech AG

https://www.marinomed.com/en

Marinomed Biotech AG is a biopharmaceutical company that develops medicinal products and medical devices for viral infectious diseases and immunological disorders. The company's innovation is driven by proprietary, patent-protected technology platforms. The Marinosolv platform enhances the solubility and bioavailability of poorly soluble compounds, enabling the development of treatments for immunological conditions such as allergies, asthma, and inflammatory diseases. The virology platform is the basis for therapies targeting viral respiratory infections. Marinomed maintains a development pipeline, has globally marketed therapeutics, and offers its technology through partnerships and services via its Solv4U unit.

Recent filings

Filing Released Lang Actions
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2026-04-30 English
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 135 Abs. 1 BörseG mit dem Ziel der europaweiten Verbreitung
Declaration of Voting Results & Voting Rights Announcements
2026-04-30 German
Release according to Article 135, Section 1 BorseG with the objective of Europe-wide distribution
Regulatory Filings
2026-04-30 English
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
Annual Report Classification · 1% confidence The document is titled 'Marinomed Biotech AG Jahresfinanzbericht 2025' (Annual Financial Report 2025). It contains a detailed 'Lagebericht' (Management Report) covering business development, strategy, risks, and corporate structure, as well as sections for the 'Jahresabschluss' (Annual Financial Statements) including the balance sheet and profit/loss statement. Given the comprehensive nature of the report, the inclusion of financial statements, and the fact that it is the primary annual reporting document for the company, it is classified as an Annual Report (10-K). FY 2025
2026-04-22 German
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes
Annual Report Classification · 1% confidence The document is titled 'Jahresfinanzbericht 2025' (Annual Financial Report 2025) for Marinomed Biotech AG. It contains a comprehensive 'Lagebericht' (Management Report) and 'Jahresabschluss' (Financial Statements), including a balance sheet, profit and loss statement, and audit opinion. It is a full-year financial report, not an announcement or a summary, and therefore qualifies as an Annual Report (10-K equivalent in this taxonomy). FY 2025
2026-04-22 German
Report Publication Announcement 2026
Report Publication Announcement Classification · 1% confidence The document is a brief announcement under Article 124 BörseG stating that the Annual financial report is now available at given URLs. It does not include the report itself but merely provides links and publication notice. It fits the “Report Publication Announcement” category per the menu-vs-meal rule.
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.